Latest CSL Limited Stories
The global plasma fractionation market is divided on the basis of product, application, and end user.
DALLAS, January 5, 2015 /PRNewswire/ -- ReportsnReports.com adds "Plasma Fractionation Market by Product (Albumin, Immunoglobulin, Factor VIII, Protease Inhibitors), Application
DALLAS, December 16, 2014 /PRNewswire/ -- According to the new market research report The "Plasma Fractionation Market by Product (Albumin, Immunoglobulin, Factor VIII,
CSL Behring Continues Improving Patient Well-Being; Key Milestone Achieved in PROLONG-9FP, Company's Recombinant Factor IX Fusion Protein Development Program KING OF PRUSSIA,
Led by CSL Behring performance, the company focuses on sustainable business practices, strong results to provide patients with lifesaving, life-enhancing therapies around the world. KING OF
Designation Helps Improve Patient Access to Kcentra in the Inpatient Hospital Setting KING OF PRUSSIA, Pa., Dec.
Two New Research Studies Provide Further Support for the Potential Role of CSL112 in the Reduction of Early Recurrent Cardiovascular Events following Myocardial Infarction KING OF
CSL112 Represents a Promising Investigational Therapy That May Fill a Void in Reducing Early Recurrent Cardiovascular Events in Patients Who Have Suffered a Heart Attack KING OF PRUSSIA, Pa.,
Presentations focus on Hizentra flexible dosing regimens and push administration PRAGUE, Oct.